Large Tularemia Vaccine Contracts Among New NIAID Biodefense Awards


The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced that it has recently made several dozen awards to further strengthen the nations biodefense and emerging disease research capabilities. The new awards include grants totaling approximately $87 million for the construction of four biosafety level-3 (BSL-3) laboratories as well as two five-year contracts totaling approximately $60 million to support the development of a vaccine against tularemia, a potential agent of bioterror.

Devising medical countermeasures against biological threats, whether they arise naturally or are the result of deliberate human action, is a top priority for NIAID, says NIAID director Anthony S. Fauci, MD. These new awards support research needed to better understand and defend against disease-causing microbes and provide funds to construct facilities where such research can be performed safely.

Regional Biocontainment Laboratories

The four new labs will join nine other NIAID-funded BSL-3 labs in the Institutes Regional Biocontainment Laboratory (RBL) program. In 2002, a panel of experts convened to provide guidance to NIAID on its biodefense agenda cited insufficient BSL-3 and BSL-4 space as a major barrier to research progress. As part of its response, NIAID established the RBL program to fund the design, construction and commissioning of state-of-the-art BSL-3 labs at sites spanning the country. The institutions receiving the new awards and the principal investigators are as follows:

George Mason University, Manassas, Va./ Charles Bailey, PhD

Tufts University, North Grafton, Mass./ Sawkat Anwer, DMVH, PhD

University of Louisville, Ky./ Nancy Martin, PhD

University of Hawaii at Manoa/ James Gaines, PhD

Tularemia Vaccine Contracts

Two contracts totaling approximately $60 million have been awarded to the University of New Mexico (C. Rick Lyons, MD, principal investigator) and to DVC LLC, Frederick, Md. (Robert House, PhD, principal investigator) to support research to identify and evaluate new tularemia vaccine candidates. Tularemia, a bacterial disease, is also known as rabbit fever; symptoms include high fever, chills, aches and swollen lymph glands. Tularemia usually can be successfully treated with antibiotics. However, the bacterium that causes tularemia is regarded by experts as a potential agent of bioterror because, if aerosolized, it could cause widespread cases of more serious disease, including severe respiratory illness and systemic infections, and even death.

Additional Biodefense Research Awards

In addition to those described above, NIAIDs Fiscal Year 2005 biodefense awards include

-- Challenge Grant program awards to support further development of previously identified therapeutics, vaccines, and diagnostics against NIAID Category A, B and C priority pathogens including anthrax, smallpox and viruses that cause pandemic influenza

-- Cooperative Research program awards to stimulate research requiring multidisciplinary effort to advance promising candidate vaccines, therapeutics and other products through the product development pathway

-- Small Business Biodefense program awards

Source: National Institutes of Health

Related Videos
Jill Holdsworth, MS, CIC, FAPIC, CRCST, NREMT, CHL
Jill Holdsworth, MS, CIC, FAPIC, CRCSR, NREMT, CHL, and Katie Belski, BSHCA, CRCST, CHL, CIS
Baby visiting a pediatric facility  (Adobe Stock 448959249 by
Antimicrobial Resistance (Adobe Stock unknown)
Anne Meneghetti, MD, speaking with Infection Control Today
Patient Safety: Infection Control Today's Trending Topic for March
Infection Control Today® (ICT®) talks with John Kimsey, vice president of processing optimization and customer success for Steris.
Picture at AORN’s International Surgical Conference & Expo 2024
Infection Control Today and Contagion are collaborating for Rare Disease Month.
Related Content